Corvus Pharmaceuticals, Inc.

CRVSNASDAQ • USD
10.26 USD
↘ 0.34 (3.21%)🟢PRE MARKET (AS OF 08:47 AM EST)
🟢Market: OPEN

Corvus Pharmaceuticals, Inc. (CRVS) is currently trading at $10.26. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. CRVS is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$10.70
High?$10.92
Low?$10.26
Prev. Close?$10.60
Volume?153
Avg. Volume?1.1M
VWAP?$10.71
Rel. Volume?0.00x
Bid / Ask
Bid?$8.50 × 100
Ask?$12.42 × 100
Spread?$3.92
Midpoint?$10.46
Valuation & Ratios
Market Cap?894.1M
Shares Out?84.4M
Float?73.6M
Float %?87.5%
P/E Ratio?N/A
P/B Ratio?4.29
EPS?-$0.76
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Employees
37
Market Cap
894.1M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2016-03-23
Address
901 GATEWAY BLVD, THIRD FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 900-4520
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?31.61Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.13%Squeeze Risk
Short Interest?17.8M
Days to Cover?18.9
Free Float73.6M
Avg Daily Volume942.3K
Settlement Date2026-10-30
Financial Health
Current Ratio?13.38Strong
Quick Ratio?13.38Strong
Cash Ratio?0.97Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
42
4.29FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-13.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-30.9%WEAK▾
ROA?
S&P
3
-28.7%WEAK▾
Cash Flow & Enterprise
FCF?$-47942000
Enterprise Value?$879.1M
Fundamentals ratios updated end of day